Year-end report 2014 Full year January – December 2014

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 20, 2015 at 3:00 AM

Year-end report 2014

Full year January – December 2014 · Net asset value per share was SEK 46.09 at year-end, compared with SEK 33.47 at the previous year’s end. · The net asset value per share, adjusted for dividends of SEK 1.00 per share, increased by 40.7 per cent during the year. · Bure’s net asset value was SEK 3,291M (2,545) at year-end. · The Six Return Index rose by 15.8 per cent. · Total return on the Bure share amounted to 43.0 per cent (21.0). · The Parent Company’s profit after income taxes amounted to SEK 953.1M (503.5). Earnings per share amounted to SEK 12.72 (6.40). Fourth quarter 2014 · The net asset value per share increased by 13.1 per cent during the quarter. · The Six Return Index rose by 6.1 per cent. · Bure completed the acquisition of 20.1 per cent of Fondbolaget Fondita Ab in Finland. · Bure Financial Services was established as the holding company for the shareholdings in Catella (10.4 per cent) and Fondbolaget Fondita (20.1 per cent). · Bure divested 1 million shares in Vitrolife, 300,000 shares in Xvivo Perfusion and a smaller shareholding in PartnerTech to the management of PartnerTech. Total proceeds amounted to SEK 172M. · Bure repurchased 4,108,043 shares during the quarter. Bure’s holding thereafter amounts to a total of 4,684,068 of treasury shares, which represents 6.2 per cent of the total number of shares outstanding. Subsequent events · The net asset value per share amounted to SEK 60,06 on 19 February 2015 which corresponds to an increase of 30.3 per cent since year-end. · The Board proposes that the AGM approves an ordinary dividend of SEK 1.00 per share. · After the end of the reporting period, Bure has repurchased 563,732 shares for SEK 22.2M. Bure’s holdings of treasury shares increased as of 19 February 2015 to 5,247,800 shares, which is equal to 6.9 per cent the total number of shares outstanding in the company. This year’s increase in net asset value per share concluded at a fantastic 40.7 per cent. Strong gains in two of our long-term holdings, Mycronic (+100%) and Vitrolife (+76%), are the main contributors. This fact is particularly gratifying because it shows that long-term and persistent work really does pay off. The Six Return Index ended at +15.8 per cent. During the year we made two new portfolio company investments. In September, we invested about SEK 200M in the listed engineering group, Cavotec. Cavotec is active in a number of different market segments in which they market their internally developed systems and products. Our ambition is to work with management to take the next step in the company’s development. In addition to the investment in Cavotec, we have also returned to the financial sector. We have done this by acquiring 20 per cent of the Finnish fund manager, Fondita, and 10 per cent of Catella. Fondita has an impressive history as one of the leading independent equity fund managers in the Nordic countries. Since our investment in March, Catella, which is a listed financial advisor and asset manager, has developed very well with an increase of about 100 per cent. In connection with these investments, we created a holding company for our investments in the financial sector, Bure Financial Services AB. In 2014, we continued to repurchase our own shares. In total we have repurchased 4.7 million shares, representing 6.2 per cent of the capital, at an average price of SEK 30.55. Thanks to the divestment of 1 million shares in Vitrolife in December, we once again had about SEK 500M available for investment by year-end. Despite the current historically high asset prices, we continue to focus and work on evaluating new investments. We see, for example, many interesting situations in which Bure can play a distinct role. Finally, I want to comment on our exceptional start of the year. Bure’s net asset value per share currently amounts to SEK 60,1 representing an increase of 30,3 percent. The main cause is the development of the share price of Mycronic, which since year-end has risen by 100 per cent. I conclude that this is proof of the great efforts by all employees at Mycronic! Henrik Blomquist CEO For additional information contact Henrik Blomquist, CEO +46 8 614 00 20 Max Jonson, CFO +46 8 614 00 20 The information in this interim report is subject to the disclosure requirements of Bure Equity AB under the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. This information was publicly communicated on 20 February 2015, 8:30 a.m. CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Senior Care Location Opens in Broward County

A Personal Mission Driving Business in Hollywood Dive deep into any community, and you'll often find stories that tug at the heartstrings—especially when they're about family. That's the case with Saudia Sital, a Broward County local who's just opened Always Best Care Senior Services in Hollywood, Florida. Her journey from personal caregiver to business owner isn't just...

Surprising Week on Wall Street: Chips Drive Gains

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Matthew Callstrom Named CEO: Mayo Clinic's Next Era

Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

NueSynergy Secures Top Spot in HSA Provider Rankings

NueSynergy Earns its Stripes in 2026 It seems these days, healthcare costs are rising faster than you can say 'deductible.' In this chaotic landscape, a good HSA provider is worth its weight in gold. Enter NueSynergy, whose efforts have once again been acknowledged by Morningstar, a big name in the world of investment research. What Sets NueSynergy Apart? NueSynergy isn't...

Perpetua Reports Q3 2026 Results, Progress on Project

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

TagMaster To Acquire Kapsch's RFID Ops in NA Market

A Strategic Move in the Transportation Sector Here's a fresh shake-up for the North American transportation sector: TagMaster, alongside its U.S. subsidiary Sensys Networks, is all set to acquire Kapsch TrafficCom's RFID-focused North American components business. This isn't just a minor shuffle—this deal could ripple through the industry, promising strategic uplifts...

Lavazza 2027 Calendar: Moments of Pleasure Worldwide

Capturing Fleeting Joy Through the Lens In 2027, Lavazza sets the stage for an evocative exploration of human pleasure through its iconic calendar. Teaming up with photographers Jim Goldberg, Alex Majoli, and Paolo Pellegrin, the project spans three vibrant cities: New York, Lisbon, and Hong Kong. These masters of the lens invite us to pause and appreciate the understated...

TruGreen Finds New Growth in Birch Hill Acquisition

TruGreen's New Chapter Begins In the world of lawn care, TruGreen is sowing the seeds for a revitalized future, courtesy of its recent acquisition by Birch Hill Equity Partners. Based out of Franklin, Tennessee, this powerhouse in the green arena is set to start a fresh chapter, swapping partners like old gloves after a long, 19-year stint with Clayton, Dubilier & Rice...